Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.

Korro Bio Inc. has nominated KRRO-121 as its next development candidate, for the treatment of patients with hyperammonemia, including patients with urea cycle disorders and hepatic encephalopathy.

South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.

Genfit SA has established a research collaboration with Everzom SAS to expand its acute-on-chronic liver failure (ACLF) research via exosome-based regenerative technology. The partners plan to conduct exploratory studies to assess efficacy of Everzom’s investigational drug candidate Eviv in ACLF.

Phase II data being presented at the American Association for the Study of Liver Diseases annual meeting indicate drug development in the field of metabolic dysfunction-associated steatohepatitis (MASH) is making steady progress.

Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis.

The largest study ever conducted on light therapy for Parkinson’s disease has found that long-term use of Symbyx Biome Pty Ltd.’s non-invasive, at-home photobiomodulation (PBM) devices significantly improved mobility, anxiety, and overall symptom severity.